

Udenyca[®] Onbody[™] (pegfilgrastim-cbqv) – First-time biosimilar launch

- On February 21, 2024, [Coherus announced](#) the launch of [Udenyca Onbody \(pegfilgrastim-cbqv\)](#), a biosimilar to Amgen's [Neulasta[®] OnPro[®] \(pegfilgrastim\)](#).
- Udenyca Onbody and Neulasta OnPro share the following indications in adult patients:
 - Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
 - Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).